MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A novel nanoplatform effectively targets hepatocellular carcinoma (HCC) by inducing ferroptosis and apoptosis. This approach alleviates tumor hypoxia and enhances reactive oxygen species (ROS)-mediated cancer therapy.
Area Of Science
- Biomedical Engineering
- Nanotechnology
- Oncology
Background
- Ferroptosis plays a critical role in hepatocellular carcinoma (HCC) development and progression.
- HCC patients exhibit increased vulnerability, necessitating novel therapeutic strategies.
Purpose Of The Study
- To develop and evaluate a novel nanoplatform for HCC treatment.
- To investigate the in vitro and in vivo antitumor mechanisms of the nanoplatform.
Main Methods
- Mesoporous silica nanoparticles (MSNs) were loaded with erastin (induces ferroptosis) and HMME (sonosensitizer).
- Nanoparticles were modified with hyaluronic acid (HA) for targeted delivery, forming Erastin/HMME@MSNs-HA.
- In vitro and in vivo studies assessed antitumor efficacy and mechanisms.
Main Results
- Erastin/HMME@MSNs-HA induced cancer cell death via increased reactive oxygen species (ROS), glutathione depletion, and lipid peroxidation.
- The nanoplatform combined with ultrasound (US) treatment significantly reduced tumor growth in vivo.
- The treatment effectively alleviated tumor hypoxia and demonstrated good biocompatibility.
Conclusions
- The developed nanoplatform effectively induces apoptosis and ferroptosis, alleviating tumor hypoxia.
- This strategy provides a foundation for enhancing ROS-mediated HCC therapy.
- The nanoplatform shows promise for improving HCC treatment outcomes.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.